From a pilot study comparing the antiviral effect of interferon, acyclovir and a combination of interferon and acyclovir, it was concluded that combination therapy appears to be a highly promising treatment for chronic hepatitis B.7 As more recent controlled studies have shown that acyclovir does not enhance the therapeutic effect of interferon alone,8 the results of the pilot study could also be interpreted as indicating that a second course of interferon after short term primer interferon therapy is more effective than a single course. Therefore we investigated the effect of intermittent interferon treatment on termination of herpatitis B viral replication, measured by HBeAg seroconversion and HBV-DNA clearance from serum.
Abstract
In a European multicentre study 40 patients with HBeAg positive chronic hepatitis B virus (HBV) infection were treated with 5 mega units of lymphoblastoid a-interferon daily according to the following regimen: a four week primer course, four weeks of rest and a second course lasting 16 to 30 weeks. After 52 weeks of follow up, a response (HBeAg seroconversion and HBV-DNA negativity) was observed in 22 patients (55%). HBsAg seroconversion occurred in five patients (12.5%). One patient exhibited a relapse for serum HBeAg and HBV-DNA after cessation of treatment. According to a response prediction model, the observed response rate was not related to the selection of patients likely to respond. The initial interferon course induced a reduction of the serum HBV-DNA and HBeAg levels of 87% and 18%, respectively, leading to a significantly lower level of viral replication activity at the start of the second longterm course compared with baseline. After 24 weeks of follow up (week 16 of the second course), 19 (48%) patients exhibited a response, 13 (32%) a partial response (HBeAg <50% of initial level or HBV-DNA negative) and 8 (20%) no response. For eight of the 13 partial responders treatment was stopped at week 24 and viral replication rebounded to pretreatment values. In the last five partial responders prolongation of therapy up to week 38 led to a definite response and HBsAg seroconversion in three of the five patients. The results of this study suggest that a short primer course Patients were seen, and if indicated examined, at the outpatient clinic every two to four weeks during treatment and every four to eight weeks during the period thereafter. Laboratory assessment was performed every two weeks during the treatment period and every four to six weeks after discontinuation of therapy. On these occasions routine haematological studies were performed and serum markers of viral replication (HBeAg and HBV-DNA) and aspartate aminotransferase activity were measured. Every three months additional biochemical and virological measurements including the prothrombin time and the levels of alanine aminotransferase, albumin, bilirubin, HBsAg, and antibodies against HBsAg as well as HBeAg were performed. Liver biopsies were taken within six months of entry to the study for histological assessment.
All virological parameters were determined centrally at the Rotterdam hepatitis laboratory. HBsAg was assessed using a commercial radioimmunoassay kit (Abbott, Ill, USA). HBeAg was measured quantitatively using a radioimmunoassay (Abbott, Ill, USA). For quantification a P/N ratio (counts of patient sample/ counts of negative control sample) was determined for each patient in a fixed serum dilution. HBeAg seroconversion was defined as a P/N ratio under 2.1 for undiluted serum from two consecutive blood samples. HBV-DNA was measured by a liquid hybridisation assay using an iodine 125 probe (Abbott, Ill, USA). Antibodies to hepatitis C virus were determined, retrospectively, by enzyme immunoassay (Abbott, Ill, USA); positive results were confirmed by a recombinant immunoblot assay Patients characteristics at entry into the study 
